EVIDENCE PROFILE / PUBLISHED
Melanotan II
Melanotan II is a cyclic alpha-MSH analogue with activity at multiple melanocortin receptors; it is distinct from afamelanotide and bremelanotide products. A 1996 phase-I pilot enrolled three men and reported pigmentation plus nausea, fatigue, yawning, and erections. This sample is far too small for broad efficacy or safety conclusions.
Evidence at a glance
- Human
- LimitedOne three-person pilot study from 1996.
- Animal/cell
- Not rated
- Approved medicine
- None foundScope: the U.S. sources reviewed.
Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.
PREPPY BOY ASKS
“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”
The catalogue name is a starting point, not proof of formulation or identity. Early studies examined pigmentation and erectile responses, while current concern includes uncontrolled products and receptor-wide effects.
Identity
Melanotan II is a cyclic alpha-MSH analogue with activity at multiple melanocortin receptors; it is distinct from afamelanotide and bremelanotide products.
Biological mechanism or research interest
Early studies examined pigmentation and erectile responses, while current concern includes uncontrolled products and receptor-wide effects.
Verified approved human uses
No FDA-approved Melanotan II medicine was identified in the reviewed sources.
Investigational human evidence
A 1996 phase-I pilot enrolled three men and reported pigmentation plus nausea, fatigue, yawning, and erections. This sample is far too small for broad efficacy or safety conclusions.
Popular claims versus demonstrated findings
Tanning, appetite, and sexual-function claims outpace the limited, old, small human evidence.
Human versus animal or cell evidence
Potent receptor activity and laboratory findings do not establish a safe consumer formulation.
Limitations and known risks
FDA summarizes case reports including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism; causality and product identity can be uncertain.
